|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 801 Pennsylvania Ave, NW, Suite 325 |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 7053-12
|
||||||||
|
6. House ID# 315800000
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Chris Pernie |
Date | 4/19/2016 11:30:07 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
HR 9, the Innovation Act, regarding all biopharmaceutical related provisions.
S. 1137, Protecting American Talent and Entrepreneurship Act, regarding all biopharmaceutical related provisions.
S. 1890 Defend Trade Secrets Act of 2016, regardng all biopharmaceutical related provision.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Williams |
Mr. |
|
|
Chris |
Pernie |
|
|
|
Lane |
Penry |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions.
Agriculture Appropriations, regarding all biopharmaceutical related provisions.
H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions.
No bill, raised awareness about atrial fibrillation and stroke prevention.
H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions.
H.R.6, 21st Century Cures Initiative and Senate Innovation for a Healthier America proposal, regarding all biopharmaceutical related provisions.
No Bill, lobbied Congress on biosimilar issues including naming, labeling and interchangability.
No Bill, lobbied Congress on importation of prescription drugs.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Chris |
Pernie |
|
|
|
Paul |
Williams |
|
|
|
Lane |
Penry |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions.
H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions.
H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions.
No Bill, lobbied on price controls for biopharmaceuticals in government health care programs.
No Bill, lobbied on the proposed rule on the CMMI Medicare Part B demonstration project.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Chris |
Pernie |
|
|
|
Paul |
Williams |
|
|
|
Lane |
Penry |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions.
H.R. 719, Continuing Appropriations Act,regarding all biopharmaceutical related provisions.
H.R. 2029, Consolidates Appropriations Act, regarding all biopharmaceutical related provsions.
H.R. 3762, Restoring America's Healthcare Freedom Reconciliation Act, regarding all biopharmaceutical related provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Williams |
|
|
|
Chris |
Pernie |
|
|
|
Lane |
Penry |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
S. 995, H.R. 2146 Bipartisan Congressional Trade Priorities and Accountability Act, regarding intellectual property rights in trade agreements and international negotiations.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Williams |
|
|
|
Chris |
Pernie |
|
|
|
Lane |
Penry |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |